1. Updates From ACC

2. CVD, HF, and T2D

3. Antihyperglycemic Medications and CV Outcomes From RCTs Pre-2015

4. Antihyperglycemic Medications and Impact on HF From RCTs Pre-2015

5. EMPA-REG OUTCOME: Empagliflozin Primary MACE Outcome

6. EMPA-REG OUTCOME: Empagliflozin Attribution to MACE Reduction

7. EMPA-REG OUTCOME: Empagliflozin Hospitalization for HF

8. LEADER: Liraglutide Attribution to MACE Reduction

9. LEADER: Liraglutide Primary MACE Outcome

10. EMPA-REG OUTCOME vs LEADER

11. SUSTAIN-6: Semaglutide* Primary MACE Outcome

12. SUSTAIN-6: Semaglutide* Attribution to MACE Reduction

13. HF Benefit With Empagliflozin in Patients With and Without Established HF

14. HF Analyses LEADER and SUSTAIN-6

15. HF Analyses ELIXA -- Lixisenatide

16. FIGHT and LIVE Studies Liraglutide

17. CVD-REAL Study Questions Posed

18. CVD-REAL Study Patient Population

19. CVD-REAL Study Baseline Characteristics

20. CVD-REAL Study Contribution of SGLT2 Inhibitors

21. CVD-REAL Study HHF Primary Analysis

22. CVD-REAL Study All-Cause Death

23. CVD-REAL Study Limitations

24. Interpreting Real-World Data vs RCTs

25. CVD-REAL Study vs EMPA-REG OUTCOME

26. What to Look Forward to

27. Concluding Remarks

28. Abbreviations

29. Abbreviations (cont)